Juliana Schwaab

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 95 publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology

Published: June 21, 2026

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Journal: Frontiers in immunology

Published: May 07, 2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology

Published: March 15, 2026

Patient Journey, Treatment Patterns, and Disease Burden of Patients With Idiopathic Hypereosinophilic Syndrome.

Patient Journey, Treatment Patterns, and Disease Burden of Patients With Idiopathic Hypereosinophilic Syndrome.

Journal: EJHaem

Published: January 06, 2026

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1.

Journal: Leukemia

Published: December 11, 2025

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.

Journal: American journal of hematology

Published: May 30, 2025

Leukocytosis, Monocytosis, and Eosinophilia in Systemic Mastocytosis: Analysis of Phenotype, Genetics and Prognosis in 596 Patients From the GREM Registry.

Leukocytosis, Monocytosis, and Eosinophilia in Systemic Mastocytosis: Analysis of Phenotype, Genetics and Prognosis in 596 Patients From the GREM Registry.

Journal: The journal of allergy and clinical immunology. In practice

Published: May 23, 2025

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis.

Journal: British journal of haematology

Published: May 07, 2025

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study.

Journal: Leukemia research

Published: April 18, 2025

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

Journal: Scientific reports

Published: March 29, 2025

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals.

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals.

Journal: Current hematologic malignancy reports

Published: July 02, 2024

MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.

MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.

Journal: Annals of hematology

Published: May 20, 2024

Showing 1-12 of 95

Last Updated: 09/26/2026